Kopel S, Michowitz M, Leibovici J
Int J Immunopharmacol. 1985;7(6):801-10. doi: 10.1016/0192-0561(85)90042-6.
Determination by the immune system of chemo- and immunotherapy of a murine tumor was investigated. The effect of cyclophosphamide and levan (polyfructose) in single and combined treatment on the growth of the F10 variant of B16 melanoma was tested in splenectomized and non-splenectomized mice. Splenectomy was found to increase markedly the efficiency of all treatments, particularly the combined treatment, as judged by the delay of appearance and size of the subcutaneous tumors at the site of inoculation. Nevertheless, mortality rate was not always in correlation with the rate of local tumor evolution: some of the treated splenectomized mice died earlier than expected, with relatively small local tumors, due to enhanced metastasis. The results indicate that elements in the spleen of C57BL mice decrease the therapeutic efficiency of the drugs tested. It can be deduced that splenectomy must not be considered to increase the risk of a tumor-bearing host in all cases. On the contrary, it may improve the efficiency of cancer treatment in certain tumor-host systems.
研究了免疫系统对小鼠肿瘤化疗和免疫治疗的影响。在脾切除和未脾切除的小鼠中测试了环磷酰胺和左聚糖(多聚果糖)单药及联合治疗对B16黑色素瘤F10变体生长的影响。通过接种部位皮下肿瘤出现的延迟和大小判断,发现脾切除术显著提高了所有治疗的效率,尤其是联合治疗。然而,死亡率并不总是与局部肿瘤进展率相关:一些接受治疗的脾切除小鼠因转移增强,在局部肿瘤相对较小的情况下比预期更早死亡。结果表明,C57BL小鼠脾脏中的成分会降低所测试药物的治疗效率。可以推断,在所有情况下都不能认为脾切除术会增加荷瘤宿主的风险。相反,在某些肿瘤-宿主系统中,它可能会提高癌症治疗的效率。